RxDoctor Payments Data

Susan Prater, MD

Family Medicine · Draper, UTNPI 1841430733

Payments from drug & device makers

$4,887in general payments, 2019–2025

Across 263 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$746
  • Amgen$499
  • Lilly USA, LLC$397
  • Novo Nordisk$360
  • Pfizer$195
  • Pharming Healthcare, Inc.$184
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$4,887100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,887 in reported general payments places this provider in the 80th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$24,128
Medicare patients
85
Services billed
277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide37$39,196
EliquisApixaban33$36,477
OzempicSemaglutide19$26,273
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$6,738
JanuviaSitagliptin Phosphate12$6,709
CymbaltaDuloxetine Hcl13$4,136
Omeprazole109$2,099
Gabapentin85$2,052
Levothyroxine Sodium200$1,620
Atorvastatin Calcium178$1,359
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen55$1,287
Bupropion XlBupropion Hcl47$1,200
Duloxetine Hcl34$990
Celecoxib24$924
Losartan Potassium105$886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Cymbalta$397$43,33250 claims
PfizerEliquis$195$36,47733 claims
Novo NordiskOzempic$360$26,27319 claims
MerckJanuvia$60$6,70912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 928 family medicine providers in Utah.

Other family medicine in Draper

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →